KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $274.2 million.

  • Recursion Pharmaceuticals' Shares Outstanding (Diluted Average) rose 58.18% to $447.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.0 million, marking a year-over-year increase of 58.18%. This contributed to the annual value of $274.2 million for FY2024, which is 31.92% up from last year.
  • Recursion Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $274.2 million in FY2024, which was up 31.92% from $207.9 million recorded in FY2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $274.2 million during FY2024, and registered a low of $21.8 million during FY2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $219.2 million, with a median of $207.9 million in 2023.
  • Data for Recursion Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY surged of 475.48% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $21.8 million in 2020, then soared by 475.48% to $125.3 million in 2021, then skyrocketed by 40.04% to $175.5 million in 2022, then rose by 18.41% to $207.9 million in 2023, then surged by 31.92% to $274.2 million in 2024.